A new era of novel immunotherapies for multiple myeloma

Multiple myeloma is the second most common haematological malignancy globally, with an estimated prevalence of 450 579 cases in 2020.1 Although curative therapy is not yet available, in the past two decades an incremental increase in survival of patients with multiple myeloma due to novel therapies has occurred. In 2016, the first antibody-based immunotherapies, daratumumab and elotuzumab, were approved in the USA.2,3 Over the past decade, of the ten approved therapies, the most efficacious and transformative drugs have been those harnessing the immune system.